Citations

Clear

4847 citation(s) found for "Yu, Eric".

Proposal to optimize evaluation and treatment of Febrile infection‐related epilepsy syndrome (FIRES): A Report from FIRES workshop
Koh, Sookyong , Wirrell, Elaine , Nabbout, Rima , Muscal, Eyal , Kaliakatsos, Marios , Wickström, Ronny , Riviello, James J. , Brunklaus, Andreas , Payne, Eric T. , Valentı́n, Antonio , Wells, Elizabeth, Carpenter, Jessica L. , Lee, Kihyeong, Eschbach, Krista , Press, Craig A. , Gorman, Mark , Stredny, Coral M. , Roche, William , Mangum, Tara, Brunklaus, Andreas , Payne, Eric, Lai, Yi-Chen , Eschbach, Krista , Wirrell, Elaine C , Vezzani, Annamaria , Lai, Yi‐Chen , Roche, William

Mayo Clinic

Epilepsia Open | November 20, 2020 | Volume: 6 | Issue: 1 | Pages: 62-72

10.1002/epi4.12447 | PMID 33681649 Get It

AbstractFebrile infection‐related epilepsy syndrome (FIRES) is a rare catastrophic epileptic encephalopathy that presents suddenly in otherwise normal children and young adults causing significant neurological disability, chronic epilepsy, and high rates of mortality. To suggest a therapy protocol to improve outcome of FIRES, workshops were held in conjunction with American Epilepsy Society annual meeting between 2017 and 2019. An international group of pediatric epileptologists, pediatric neurointensivists, rheumatologists and basic scientists with interest and expertise in FIRES convened to propose an algorithm for a standardized approach to the diagnosis and treatment of FIRES. The broad differential for refractory status epilepticus (RSE) should include FIRES, to allow empiric therapies to be started early in the clinical course. FIRES should be considered in all previously healthy patients older than two years of age who present with explosive onset of seizures rapidly progressing to RSE, following a febrile illness in the preceding two weeks. Once FIRES is suspected, early administrations of ketogenic diet and anakinra (the IL‐1 receptor antagonist that blocks biologic activity of IL‐1β) are recommended.
Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial
Isganaitis, Elvira , Raghinaru, Dan, Ambler-Osborn, Louise, Pinsker, Jordan E. , Buckingham, Bruce A. , Ekhlaspour, Laya , Kudva, Yogish C., Forlenza, Gregory P. , Beck, Roy W., Kollman, Craig, Lum, John W. , Brown, Sue A. , Laffel, Lori M. , Kovatchev, Boris, Anderson, Stacey, Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Gondor-Fredrick, Linda, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Breton, Marc, Flint, Emily, Kim, Kenny, Roethke, Lindsay, Church, Mei Mei , André, Camille , Piper, Molly, Lam, David , O’Malley, Grenye , Levister, Camilla, Ogyaadu, Selassie, Lovett, Jessica, Simha, Vinaya , Dadlani, Vikash, McCrady-Spitzer, Shelly , Reid, Corey, Alonso, G. Todd, Slover, Robert H., Jost, Emily , Berget, Cari, Towers, Lindsey, Rossick-Solis, Alex, Jacobson, Tali, Town, Marissa, Tabatabai, Ideen , Keller, Jordan, Salas, Evalina, Dassau, Eyal , Passman, Samantha, Campos, Tiffany, Murphy, Carlos, Patibandla, Nandan, Borgman, Sarah, Arreaza-Rubín, Guillermo , Green, Neal, Laffel, Lori, Pinsker, Jordan, Doyle, Francis, Renard, Eric, Reznik, Yves , Lum, John, Janicek, Robert, Gabrielson, Deanna, Belle, Steven H., Castle, Jessica R. , Green, Jennifer , Legault, Laurent , Wysham, Carol , Eggerman, Thomas, Forlenza, Gregory P , Buckingham, Bruce , Wadwa, R Paul , Kudva, Yogish C. , Levy, Carol J. , Kollman, Craig , Kovatchev, Boris , Anderson, Stacey M. , Oliveri, Mary Clancy , Kumari, Kanchan , Messer, Laurel H , Jacobson, Tali, Doyle, Francis J. , Patibandla, Nandan, Laffel, Lori M. , Cobelli, Claudio , Beck, Roy W. , Willi, Steven Matthew

Mayo Clinic

Diabetes Technology & Therapeutics | November 20, 2020 | Volume: 23 | Issue: 5 | Pages: 342-349

10.1089/dia.2020.0572 | PMID 33216667 Get It

Objective: To assess the efficacy and safety of closed-loop control (CLC) insulin delivery system in adolescents and young adults with type 1 diabetes. Research Design and Methods: Prespecified subanalysis of outcomes in adolescents and young adults aged 14–24 years old with type 1 diabetes in a previously published 6-month multicenter randomized trial. Participants were randomly assigned 2:1 to CLC (Tandem Control-IQ) or sensor augmented pump (SAP, various pumps+Dexcom G6 CGM) and followed for 6 months. Results: Mean age of the 63 participants was 17 years, median type 1 diabetes duration was 7 years, and mean baseline HbA1c was 8.1%. All 63 completed the trial. Time in range (TIR) increased by 13% with CLC versus decreasing by 1% with SAP (adjusted treatment group difference = +13% [+3.1 h/day]; 95% confidence interval [CI] 9–16, P < 0.001), which largely reflected a reduction in time >180 mg/dL (adjusted difference −12% [−2.9 h/day], P < 0.001). Time <70 mg/dL decreased by 1.6% with CLC versus 0.3% with SAP (adjusted difference −0.7% [−10 min/day], 95% CI −1.0% to −0.2%, P = 0.002). CLC use averaged 89% of the time for 6 months. The mean adjusted difference in HbA1c after 6 months was 0.30% in CLC versus SAP (95% CI −0.67 to +0.08, P = 0.13). There was one diabetic ketoacidosis episode in the CLC group. Conclusions: CLC use for 6 months was substantial and associated with improved TIR and reduced hypoglycemia in adolescents and young adults with type 1 diabetes. Thus, CLC has the potential to improve glycemic outcomes in this challenging age group. The clinical trial was registered with ClinicalTrials.gov (NCT03563313).
Three Medicolegal Cases of Searching for the Stone: Lessons Learned Along the Journey
Jacobson, Ashley , Moore, Gregory P. , Boie, Eric T., Sakamoto, Ayumi , Jacobson, Ashley A, Sakamoto, Ayumi E, Moore, Gregory

Mayo Clinic

Clinical Practice and Cases in Emergency Medicine | November 17, 2020 | Volume: 4 | Issue: 4 | Pages: 505-508

10.5811/cpcem.2020.9.48652 | PMID 33217257 Get It

We present three medicolegal cases of medical negligence settled out of court. These cases all involved patients who presented to the emergency department (ED) with a suspected diagnosis of kidney stone. Highlighted are the importance of patient communication, addressing incidental findings found during a patient’s ED visit, anticipating complications, and the need for thorough documentation.
Abstract IA-11: An exception to the rule: A coding functional variant at a pancreatic cancer GWAS locus
Jermusyk, Ashley , Zhong, Jun, Gordon, Naomi, Abdolalizadeh, Ehssan, O’Brien, Aidan , Collins, Irene , Eiser, Daina, Jacobs, Eric J. , Li, Donghui , Du, Mengmeng , Wolpin, Brian M. , Shi, Jianxin , Petersen, Gloria M. , Zhong, Jun , Zhong, Jun , Connelly, Katelyn E. , Perera, Sumeth , Zhang, Tongwu , Hoskins, Jason W. , Yuan, Chen , Risch, Harvey A. , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Smith, Jill Palmer , Chanock, Stephen Jacob , Westlake, Christopher J. , Ámundadóttir, Laufey T.

Mayo Clinic

Cancer Research | November 17, 2020 | Volume: 80 | Issue: 22_Supplement | Pages: IA-11-IA-11

10.1158/1538-7445.panca20-ia-11 Get It

Abstract Genome wide association studies (GWAS) in 9,013 pancreatic cancer patients and 12,452 controls of European ancestry have discovered over 20 risk loci in the human genome. Here, we fine mapped one such locus on chromosome 16q23.1 in the vicinity of two Chymotrypsinogen precursor genes, CTRB1 and CTRB2. We fine-mapped this locus to rs72802365 (P=2.51x10-17, OR=1.36, 95% CI=1.31-1.40) and identified colocalization (PP=87%) with aberrant exon 5→7 CTRB2 splicing in pancreatic tissues. Imputation of a 584 bp insertion/deletion variant overlapping exon 6 of CTRB2 into the GWAS datasets resulted in a highly significant association with pancreatic cancer risk (P=2.83x10-16, OR=1.36, 95% CI=1.31-1.42), indicating that it may underlie this signal. Exon skipping attributable to the deletion (risk) allele introduces a premature stop codon in exon 7 of CTRB2, yielding a truncated chymotrypsin B2 protein that lacks chymotrypsin activity, is poorly secreted, and accumulates intracellularly in the endoplasmic reticulum (ER). The intracellular accumulation of a nonfunctional chymotrypsinogen B2 protein may lead to ER stress and pancreatic inflammation, which in turn, may explain the increased pancreatic cancer risk in carriers of CTRB2 exon 6 deletion alleles. Citation Format: Ashley Jermusyk, Jun Zhong, Naomi Gordon, Katelyn Connelly, Sumeth Perera, Ehssan Abdolalizadeh, Tongwu Zhang, Aidan O'Brien, Jason Hoskins, Irene Collins, Daina Eiser, Chen Yuan, Harvey Risch, Eric J. Jacobs, Donghui Li, Mengmeng Du, Rachael Stolzenberg-Solomon, Alison P. Klein, Jill P. Smith, Brian M. Wolpin, Stephen J. Chanock, Jianxin Shi, Gloria M. Petersen, Christopher Westlake, Laufey T. Amundadottir. An exception to the rule: A coding functional variant at a pancreatic cancer GWAS locus [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2020 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2020;80(22 Suppl):Abstract nr IA-11.
Biphasic cortical macro‐ and microstructural changes in autosomal dominant Alzheimer's disease
Montal, Víctor , Pegueroles, Jordi , Bejanin, Alexandre , Alcolea, Daniel , Carmona‐Iragui, María , Clarimón, Jordi , Xiong, Chengjie , Cruchaga, Carlos , Graff‐Radford, Neill R. , Noble, James M. , Laske, Christoph , Salloway, Stephen , Ances, Beau M. , McDale, Eric, Bateman, Randall J. , Blesa, Rafael , Sánchez‐Valle, Raquel , Fortea, Juan , (DIAN), for the Dominantly Inherited Alzheimer Network, Pegueroles, Jordi , Bejanin, Alexandre , Alcolea, Daniel , Clarimón, Jordi , Schofield, Peter R , Blesa, Rafael , Sánchez-Valle, Raquel , Lleó, Alberto , Fortea, Juan , Cruchaga, Carlos , Bateman, Randall J , Xiong, Chengjie , Ances, Beau M , Vilaplana, Eduard , Lee, Jae‐Hong , Allegri, Ricardo , Karch, Celeste M. , Schofield, Peter R. , Benzinger, Tammie L.S. , Lleó, Alberto , (DIAN), for the Dominantly Inherited Alzheimer Network, Noble, James M

Mayo Clinic

Alzheimer's & Dementia | November 16, 2020 | Volume: 17 | Issue: 4 | Pages: 618-628

10.1002/alz.12224 | PMID 33196147 Get It

Abstract INTRODUCTION A biphasic model for brain structural changes in preclinical Alzheimer's disease (AD) could reconcile some conflicting and paradoxical findings in observational studies and anti‐amyloid clinical trials. METHODS In this study we tested this model fitting linear versus quadratic trajectories and computed the timing of the inflection points vertexwise of cortical thickness and cortical diffusivity—a novel marker of cortical microstructure—changes in 389 participants from the Dominantly Inherited Alzheimer Network. RESULTS In early preclinical AD, between 20 and 15 years before estimated symptom onset, we found increases in cortical thickness and decreases in cortical diffusivity followed by cortical thinning and cortical diffusivity increases in later preclinical and symptomatic stages. The inflection points 16 to 19 years before estimated symptom onset are in agreement with the start of tau biomarker alterations. DISCUSSION These findings confirm a biphasic trajectory for brain structural changes and have direct implications when interpreting magnetic resonance imaging measures in preventive AD clinical trials.
Epilepsy with myoclonic‐atonic seizures (Doose syndrome): Clarification of diagnosis and treatment options through a large retrospective multicenter cohort
Nickels, Katherine , Kossoff, Eric H. , Eschbach, Krista , Joshi, Charuta , Eschbach, Krista , Nickels, Katherine C

Mayo Clinic

Epilepsia | November 15, 2020 | Volume: 62 | Issue: 1 | Pages: 120-127

10.1111/epi.16752 | PMID 33190223 Get It

AbstractObjectiveEpilepsy with myoclonic‐atonic seizures (EMAS) is a rare childhood onset epileptic encephalopathy. There is no clear consensus for recommended treatments, and pharmacoresistance is common. To better assess the clinical phenotype, most effective treatment, and determinants of cognitive and seizure outcomes, three major pediatric epilepsy centers combined data, creating the largest cohort of patients with EMAS ever studied to date.MethodsAuthors performed a retrospective chart review of patients with EMAS who received care at the authors’ institutions.ResultsA total of 166 children were identified. Global developmental delay (>1 domain) was present in 2% of children at onset and 49% during the course of the disease. Afebrile seizures occurred after the age of 2 years in 88%, generalized tonic‐clonic seizures in 60%, and drop attack or myoclonic seizures in 30%. At onset, electroencephalography (EEG) found 28% normal, background slowing in 20%, and epileptiform discharges or seizures in 69%. Subsequent EEG found slowing in 62% and discharges or seizures in 90%. Response (>50% seizure reduction) to the first three antiseizure drugs (ASDs) was 26% (levetiracetam, 17%; valproic acid, 31%; other ASDs combined, 26%). Diet therapy was used as a second or third therapy in 19% and ultimately used in 57%; response was 79%, significantly greater than the first three ASDs (P = .005, χ2). Seizure freedom occurred in 57% and was less likely in the case of persistent global developmental delays (P < .001), seizure recorded on subsequent EEGs (P = .027), and failure to respond to diet therapy (P = .005). Development was normal in 47%, and 12% had delays in one domain, which was less likely in the case of global developmental delay after epilepsy onset (P < .001) and failure to achieve seizure freedom (P < .001).SignificanceThis large cohort of children with EMAS clarifies areas of variability in practice. Diet therapy is by far the most effective treatment; failure to respond was associated with failure to attain seizure freedom. This therapy should be used early in the treatment in EMAS. This study also identified a bidirectional link between cognitive and seizure outcomes.
Abstract 12820: Beta Blocker Use and Peri-operative Outcomes in Cancer Patients Receiving Immunotherapy
Oren, Ohad , Molina, Julian R. , Oren, Michal, Bailey, Kent R. , Kopecký, S, Yang, Eric H.

Mayo Clinic

Circulation | November 12, 2020 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.12820 Get It

Introduction: The impact of beta blocker use on surgical outcomes of cancer patients receiving immunotherapy is unknown. Hypothesis: Beta blocker use is associated with lower post-operative mortality in cancer patients on immunotherapy. Methods: We used an institutional Advanced Cohort Explorer to identify all patients who underwent any surgical procedure less than 90 days after receiving immunotherapy. Data on the procedure performed as well as the post-operative outcome were collected and analyzed per the pre-operative beta blocker use status. Results: A total of 233 patients underwent surgery between 09/2011-06/2019. Mean age was 64.7 years (range: 16-92). The most common cancer diagnoses were lung (48, 44.4%), melanoma (49, 45.4%) and kidney (11, 10.2%). Immunotherapy medications were pembrolizumab ( 127, 54.5%), nivolumab (51, 21.9%), ipilimumab (43, 18.5%), atezolizumab (11, 4.7%) and avelumab (1, 0.43%). Pre-operative beta blocker use was documented in 140 (60.1%) patients. Most common surgical procedures were skin resection (75, 32.1%), wound repair (47, 20.2%), vascular procedures (36, 15.5%), urethral procedures 16 (6.9%) and sentinel lymph node biopsies (10, 4.3%). The 30-day mortality rate was 10.3% (24 deaths). In a multi-variable logistic regression analysis, pre-operative use of beta blockers was associated with a lower risk of death within 30 days from surgery (OR 0.34, CI 0.13-0.87, P=0.024). 30-day mortality rates were higher in patients undergoing vascular (50%, 17 of 34) versus non-vascular (3.5%, 7 of 199) procedures (P<0.0001) in a Chi Square test. Conclusions: Beta blocker use is associated with a lower 30-day mortality rate after surgical procedures in cancer patients treated with immunotherapy. Further investigation is warranted.
Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy
Ammirati, Enrico , Frigerio, Maria , Basso, Cristina , Birnie, David H. , Friedrich, Matthias G. , Lehtonen, Jukka , Moslehi, Javid J. , Rimoldi, Ornella , Schultheiß, Heinz‐Peter , Tschöpe, Carsten , Camici, Paolo G. , Tschöpe, Carsten , Ammirati, Enrico , Basso, Cristina , Adler, Eric D , Brambatti, Michela , Klingel, Karin , Pedrotti, Patrizia , Cooper, Leslie T.

Mayo Clinic

Circulation: Heart Failure | November 12, 2020 | Volume: 13 | Issue: 11 | Pages: No page available

10.1161/circheartfailure.120.007405 | PMID 33176455 Get It

Myocarditis is an inflammatory disease of the heart that may occur because of infections, immune system activation, or exposure to drugs. The diagnosis of myocarditis has changed due to the introduction of cardiac magnetic resonance imaging. We present an expert consensus document aimed to summarize the common terminology related to myocarditis meanwhile highlighting some areas of controversies and uncertainties and the unmet clinical needs. In fact, controversies persist regarding mechanisms that determine the transition from the initial trigger to myocardial inflammation and from acute myocardial damage to chronic ventricular dysfunction. It is still uncertain which viruses (besides enteroviruses) cause direct tissue damage, act as triggers for immune-mediated damage, or both. Regarding terminology, myocarditis can be characterized according to etiology, phase, and severity of the disease, predominant symptoms, and pathological findings. Clinically, acute myocarditis (AM) implies a short time elapsed from the onset of symptoms and diagnosis (generally <1 month). In contrast, chronic inflammatory cardiomyopathy indicates myocardial inflammation with established dilated cardiomyopathy or hypokinetic nondilated phenotype, which in the advanced stages evolves into fibrosis without detectable inflammation. Suggested diagnostic and treatment recommendations for AM and chronic inflammatory cardiomyopathy are mainly based on expert opinion given the lack of well-designed contemporary clinical studies in the field. We will provide a shared and practical approach to patient diagnosis and management, underlying differences between the European and US scientific statements on this topic. We explain the role of histology that defines subtypes of myocarditis and its prognostic and therapeutic implications.
Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial
Sherman, Eric J. , Pei, Xin , Grkovski, Milan , Paudyal, Ramesh , Katabi, Nora , Yamaguchi, Takafumi N. , Daniel, J. , Lee, Simon , Shah, Rachna , Ratnakumar, Abhirami , Salcedo, Adriana , Tsai, C. Jillian , McBride, Sean M. , Boyle, Jay, Singh, Bhuvanesh , Damerla, Rama Rao , Paula, Arnaud Da Cruz , Price, Katharine A. , Moore, Eric J. , García, Joaquín J. , Foote, Robert L. , Humm, John L. , Shukla‐Dave, Amita , Pfister, David G. , Lee, Nancy Y. , Pei, Xin , Grkovski, Milan , Paudyal, Ramesh , Yamaguchi, Takafumi N , Ma, Daniel , Shah, Rachna , Kumar, Rahul , Kuo, Fengshen , Ratnakumar, Abhirami , Tsai, Chiaojung J , Morris, Luc G T , Higginson, Daniel S , Price, Katharine, Moore, Eric J , Foote, Robert , Boutros, Paul C , Shukla-Dave, Amita , Riaz, Nadeem , Schöder, Heiko , Selenica, Pier , Kumar, Rahul , Kuo, Fengshen , Aleynick, Nathan , Brown, David N. , Zhang, Zhigang , Hatzoglou, Vaios , Liu, Lydia , Higginson, Daniel S. , Ho, Alan L. , Wong, Richard J. , Chan, Timothy An-thy , Powell, Simon N. , Boutros, Paul C. , Reis‐Filho, Jorge S. , Tsai, CJillian

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 11, 2020 | Volume: 113 | Issue: 6 | Pages: 742-751

10.1093/jnci/djaa184 | PMID 33429428 Get It

Abstract Background Patients with human papillomavirus–related oropharyngeal cancers have excellent outcomes but experience clinically significant toxicities when treated with standard chemoradiotherapy (70 Gy). We hypothesized that functional imaging could identify patients who could be safely deescalated to 30 Gy of radiotherapy. Methods In 19 patients, pre- and intratreatment dynamic fluorine-18-labeled fluoromisonidazole positron emission tomography (PET) was used to assess tumor hypoxia. Patients without hypoxia at baseline or intratreatment received 30 Gy; patients with persistent hypoxia received 70 Gy. Neck dissection was performed at 4 months in deescalated patients to assess pathologic response. Magnetic resonance imaging (weekly), circulating plasma cell-free DNA, RNA-sequencing, and whole-genome sequencing (WGS) were performed to identify potential molecular determinants of response. Samples from an independent prospective study were obtained to reproduce molecular findings. All statistical tests were 2-sided. Results Fifteen of 19 patients had no hypoxia on baseline PET or resolution on intratreatment PET and were deescalated to 30 Gy. Of these 15 patients, 11 had a pathologic complete response. Two-year locoregional control and overall survival were 94.4% (95% confidence interval = 84.4% to 100%) and 94.7% (95% confidence interval = 85.2% to 100%), respectively. No acute grade 3 radiation–related toxicities were observed. Microenvironmental features on serial imaging correlated better with pathologic response than tumor burden metrics or circulating plasma cell-free DNA. A WGS-based DNA repair defect was associated with response (P = .02) and was reproduced in an independent cohort (P = .03). Conclusions Deescalation of radiotherapy to 30 Gy on the basis of intratreatment hypoxia imaging was feasible, safe, and associated with minimal toxicity. A DNA repair defect identified by WGS was predictive of response. Intratherapy personalization of chemoradiotherapy may facilitate marked deescalation of radiotherapy.
ENSAT registry-based randomized clinical trials for adrenocortical carcinoma
Baudin, Éric , Chrisoulidou, Alexandra , Angelousi, Anna , Lamas, Cristina , Dijkum, Els J.�M. Nieveen van , Ceccato, Filippo , Tiberi, Guido A M, Ettaieb, Hester, Kiriakopoulos, Andreas , Kaštelan, Darko , Osher, Esthr, Yiannakopoulou, Eugenia , Arnaldi, Giorgio , Assié, Guillaume , Bourdeau, Isabelle , Newell‐Price, John , Nowak, Karolina M. , Romero, Mario, Martino, Maria Cristina De , Bugalho, Maria João , Dennedy, Michael Conall , Loli, Paula, Rodien, Patrice , Feelders, Richard A. , Aylwin, Simon , Morelli, Valentina , Vroonen, Laurent , Trofimiuk–Müldner, Małgorzata , Kroiß, Matthias , Mihai, Radu , Beuschlein, Felix , Ceccato, Filippo , Kroiss, Matthias , Dennedy, M Conall , Beuschlein, Felix , Newell-Price, John , Kastelan, Darko , Crona, Joakim , Terzolo, Massimo , Ronchi, Cristina L. , Borson‐Chazot, Françoise , Reimondo, Giuseppe , Canu, Letizia , Paiva, Isabel , Sherlock, Mark , Vantyghem, Marie‐Christine , Krijger, Ronald R. de , Slycke, Sam Van , Shafigullina, Zulfiya R. , Bancos, Irina , Quinkler, Marcus , Luconi, Michaela , Naruse, Mitsuhide , Igaz, Péter , Casa, Silvia Della , Berruti, Alfredo , Faßnacht, Martin

Mayo Clinic

European Journal of Endocrinology | November 9, 2020 | Volume: 184 | Issue: 2 | Pages: R51-R59

10.1530/eje-20-0800 | PMID 33166271 Get It

Adrenocortical carcinoma (ACC) is an orphan disease lacking effective systemic treatment options. The low incidence of the disease and high cost of clinical trials are major obstacles in the search for improved treatment strategies. As a novel approach, registry-based clinical trials have been introduced in clinical research, so allowing for significant cost reduction, but without compromising scientific benefit. Herein, we describe how the European Network for the Study of Adrenal Tumours (ENSAT) could transform its current registry into one fit for a clinical trial infrastructure. The rationale to perform randomized registry-based trials in ACC is outlined including an analysis of relevant limitations and challenges. We summarize a survey on this concept among ENSAT members who expressed a strong interest in the concept and rated its scientific potential as high. Legal aspects, including ethical approval of registry-based randomization were identified as potential obstacles. Finally, we describe three potential randomized registry-based clinical trials in an adjuvant setting and for advanced disease with a high potential to be executed within the framework of an advanced ENSAT registry. Thus we, therefore, provide the basis for future registry-based trials for ACC patients. This could ultimately provide proof-of-principle of how to perform more effective randomized trials for an orphan disease.